Crossmark

Kalinix®, an innovative, intelligent, non-invasive, and self-adaptive medical device for effective OSA management

Crossref DOI link: https://doi.org/10.1007/s11325-026-03687-y

Published Online: 2026-04-29

Published Print: 2026-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hermosa, Juan Luis Rodríguez

Rubio, Myriam Calle

Cidranes, Ernesto Delgado

Walther, José Luis Álvarez-Sala

Blasco, Víctor Javier Montero

Uriel, María Ángela Velacoracho

Rondán, Baldomero Fernández
Funding

Funding for this research was provided by:

Torytrans S.L.
License Information

Text and Data Mining valid from 2026-04-29

Version of Record valid from 2026-04-29
More Information

Article History

Received: 22 September 2025

Revised: 20 February 2026

Accepted: 15 April 2026

First Online: 29 April 2026

Declarations

:

: The project was approved by the Ethics Committee of the Clinical Hospital of San Carlos (C.I. 20/485-EC_P) on July 24, 2021 and authorized by the Spanish Agency of Medicines and Medical Devices (AEMPS; 835/20/EC) on August 28, 2021.

: All participants signed an informed consent prior to the enrollment in the study, in accordance with the principles of the Declaration of Helsinki and Spain’s new Organic Law 3/2018 on the Protection of Personal Data and the Guarantee of Digital Rights, effective since December 7, 2018.

: JLRH has received speaker fees or consulting fees or support for attending meetings from AstraZeneca, Bial, CSL Behring, GlaxoSmithKline, Grifols, Menarini and Zambon. MCR has received speaker fees or consulting fees or support for attending meetings from AstraZeneca, Bial, Chiesi, CSL Behring, Gebro, GlaxoSmithKline, Menarini, Grifols, Sanofi and Zambon. EDC, JLAW, VJM, MAV and BF declare that they have no competing interests. VJMB and MAVU are employees of Torytrans S.L.

Document is current

Any future updates will be listed below